GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Medexus Pharmaceuticals Inc (OTCPK:MEDXF) » Definitions » Asset Turnover

Medexus Pharmaceuticals (Medexus Pharmaceuticals) Asset Turnover : 0.15 (As of Dec. 2023)


View and export this data going back to 2017. Start your Free Trial

What is Medexus Pharmaceuticals Asset Turnover?

Asset Turnover measures how quickly a company turns over its asset through sales. It is calculated as Revenue divided by Total Assets. Medexus Pharmaceuticals's Revenue for the three months ended in Dec. 2023 was $25.2 Mil. Medexus Pharmaceuticals's Total Assets for the quarter that ended in Dec. 2023 was $163.3 Mil. Therefore, Medexus Pharmaceuticals's Asset Turnover for the quarter that ended in Dec. 2023 was 0.15.

Asset Turnover is linked to ROE % through Du Pont Formula. Medexus Pharmaceuticals's annualized ROE % for the quarter that ended in Dec. 2023 was -8.33%. It is also linked to ROA % through Du Pont Formula. Medexus Pharmaceuticals's annualized ROA % for the quarter that ended in Dec. 2023 was -1.31%.


Medexus Pharmaceuticals Asset Turnover Historical Data

The historical data trend for Medexus Pharmaceuticals's Asset Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Medexus Pharmaceuticals Asset Turnover Chart

Medexus Pharmaceuticals Annual Data
Trend Dec13 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
Asset Turnover
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.55 0.53 0.59 0.53 0.72

Medexus Pharmaceuticals Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Asset Turnover Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.20 0.19 0.19 0.18 0.15

Competitive Comparison of Medexus Pharmaceuticals's Asset Turnover

For the Drug Manufacturers - Specialty & Generic subindustry, Medexus Pharmaceuticals's Asset Turnover, along with its competitors' market caps and Asset Turnover data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Medexus Pharmaceuticals's Asset Turnover Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Medexus Pharmaceuticals's Asset Turnover distribution charts can be found below:

* The bar in red indicates where Medexus Pharmaceuticals's Asset Turnover falls into.



Medexus Pharmaceuticals Asset Turnover Calculation

Asset Turnover measures how quickly a company turns over its asset through sales.

Medexus Pharmaceuticals's Asset Turnover for the fiscal year that ended in Mar. 2023 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (A: Mar. 2023 )/( (Total Assets (A: Mar. 2022 )+Total Assets (A: Mar. 2023 ))/ count )
=108.096/( (139.225+161.329)/ 2 )
=108.096/150.277
=0.72

Medexus Pharmaceuticals's Asset Turnover for the quarter that ended in Dec. 2023 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (Q: Dec. 2023 )/( (Total Assets (Q: Sep. 2023 )+Total Assets (Q: Dec. 2023 ))/ count )
=25.211/( (166.178+160.377)/ 2 )
=25.211/163.2775
=0.15

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Companies with low profit margins tend to have high Asset Turnover, while those with high profit margins have low Asset Turnover. Companies in the retail industry tend to have a very high turnover ratio.


Medexus Pharmaceuticals  (OTCPK:MEDXF) Asset Turnover Explanation

Asset Turnover is linked to ROE % through Du Pont Formula.

Medexus Pharmaceuticals's annulized ROE % for the quarter that ended in Dec. 2023 is

ROE %**(Q: Dec. 2023 )
=Net Income/Total Stockholders Equity
=-2.136/25.6515
=(Net Income / Revenue)*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-2.136 / 100.844)*(100.844 / 163.2775)*(163.2775/ 25.6515)
=Net Margin %*Asset Turnover*Equity Multiplier
=-2.12 %*0.6176*6.3652
=ROA %*Equity Multiplier
=-1.31 %*6.3652
=-8.33 %

Note: The Net Income data used here is four times the quarterly (Dec. 2023) net income data. The Revenue data used here is four times the quarterly (Dec. 2023) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** The ROE % used above is for Du Pont Analysis only. It is different from the defined ROE % page on our website, as here it uses Net Income instead of Net Income attributable to Common Stockholders in the calculation.

It is also linked to ROA % through Du Pont Formula:

Medexus Pharmaceuticals's annulized ROA % for the quarter that ended in Dec. 2023 is

ROA %(Q: Dec. 2023 )
=Net Income/Total Assets
=-2.136/163.2775
=(Net Income / Revenue)*(Revenue / Total Assets)
=(-2.136 / 100.844)*(100.844 / 163.2775)
=Net Margin %*Asset Turnover
=-2.12 %*0.6176
=-1.31 %

Note: The Net Income data used here is four times the quarterly (Dec. 2023) net income data. The Revenue data used here is four times the quarterly (Dec. 2023) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Therefore, it is a good sign if a company's Asset Turnover is consistent or even increases. If a company's asset grows faster than sales, its Asset Turnover will decline, which can be a warning sign.


Medexus Pharmaceuticals Asset Turnover Related Terms

Thank you for viewing the detailed overview of Medexus Pharmaceuticals's Asset Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.


Medexus Pharmaceuticals (Medexus Pharmaceuticals) Business Description

Traded in Other Exchanges
Address
35 Nixon Road, Suite 1, Bolton, ON, CAN, L7E 1K1
Medexus Pharmaceuticals Inc is an innovative and rare disease pharmaceutical company with a strong North American commercial platform and a portfolio of proven best-in-class products. The company's focus is on the therapeutic areas of hematology, auto-immune diseases, and allergy.

Medexus Pharmaceuticals (Medexus Pharmaceuticals) Headlines

From GuruFocus

Medexus Schedules Third Fiscal Quarter 2023 Conference Call

By GlobeNewswire GlobeNewswire 01-31-2023

Medexus Welcomes Two New Board Members

By Stock market mentor Stock market mentor 02-06-2023

Medexus Expects Record Revenue for Fiscal Q3 2023 and Provides Business Update

By Stock market mentor Stock market mentor 01-12-2023

Medexus Secures Public Reimbursement for Cuvposa� in Quebec

By Stock market mentor Stock market mentor 02-01-2023

Treosulfan Pivotal Study Results Published

By GuruFocusNews GuruFocusNews 06-16-2022

Treosulfan NDA Resubmitted to FDA

By PurpleRose PurpleRose 07-25-2022

Medexus Schedules Fourth Quarter and Fiscal Year 2022 Conference Call

By GuruFocusNews GuruFocusNews 07-04-2022